Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Race Oncology Ltd

Healthcare AU RAC

2.36AUD
0.04(1.72%)

Last update at 2026-03-11T05:10:00Z

Day Range

2.312.42
LowHigh

52 Week Range

0.924.90
LowHigh

Fundamentals

  • Previous Close 2.32
  • Market Cap446.99M
  • Volume28964
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.85955M
  • Revenue TTM3.48M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 2.97M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.78726M -17.82300M -9.92342M -11.20198M -6.34032M
Minority interest - - - - -
Net income -4.78726M -13.81900M -9.92342M -11.20198M -6.34032M
Selling general administrative 0.74M 0.91M 1.44M 3.78M 2.74M
Selling and marketing expenses 0.25M 0.43M 0.32M 0.18M 0.17M
Gross profit 5.41M 2.22M 1.11M -0.28245M -0.23269M
Reconciled depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Ebit -4.71509M -14.48420M -13.64964M -11.96370M -6.78405M
Ebitda -4.43389M -14.20300M -13.36845M -11.68250M -6.50286M
Depreciation and amortization 0.28M 0.28M 0.28M 0.28M 0.28M
Non operating income net other - - - - -
Operating income -3.77183M -17.83257M -10.47578M -11.20289M -6.35885M
Other operating expenses 9.81M 17.83M -9.59670M -9.98318M -5.50640M
Interest expense - - - 0.05M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.79M 0.83M 0.59M 0.05M 0.02M
Net interest income 0.79M 0.83M 0.59M 0.05M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.25456M -4.00300M -0.59184M -0.05391M -0.01885M
Total revenue 6.04M 4.00M 3.13M 0.71M 0.39M
Total operating expenses 9.18M 17.55M 13.65M 11.96M 6.78M
Cost of revenue 0.64M 0.28M 2.03M 0.99M 0.62M
Total other income expense net -1.01542M -4.44200M 3.13M 0.71M 0.42M
Discontinued operations - - - - -
Net income from continuing ops -4.78726M -13.81934M -9.92342M -11.20198M -6.34032M
Net income applicable to common shares -4.78726M -13.81934M -9.92343M -11.20198M -6.34032M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 17.49M 20.23M 26.64M 37.52M 14.25M
Intangible assets 2.53M - 3.09M 3.37M 3.66M
Earning assets - - - - -
Other current assets - 0.12M - 0.55M 1.14M
Total liab 1.48M 1.92M 1.15M 1.42M 0.52M
Total stockholder equity 16.01M 18.31M 25.49M 36.11M 13.72M
Deferred long term liab - - - - -
Other current liab - 0.67M 0.51M 0.58M 0.21M
Common stock - 66.95M 61.71M 62.02M 31.50M
Capital stock 68.49M - 61.71M 62.02M 31.50M
Retained earnings -62.20542M -57.41816M -43.59882M -33.67540M -22.46644M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 13.67M 1.39M 21.52M 33.54M 9.32M
Cash and equivalents - - - - -
Total current liabilities 1.45M 1.87M 1.15M 1.42M 0.52M
Current deferred revenue - - - - -
Net debt - -1.38883M -21.52037M -33.54079M -9.32244M
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - -18.11033M -28.34141M -9.02898M
Property plant equipment - - - - -
Total current assets 14.96M 17.42M 23.54M 34.15M 10.59M
Long term investments - - - - -
Net tangible assets - - 22.39M 32.73M 10.07M
Short term investments - 15.80M - - -
Net receivables - 0.11M 1.70M 0.06M 0.13M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.46M 1.20M 0.64M 0.83M 0.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 8.78M 7.38M 7.77M 4.69M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -3.09315M -3.37435M -3.65555M
Deferred long term asset charges - - - - -
Non current assets total 2.53M 2.81M 3.09M 3.37M 3.66M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M - - - -
Change to liabilities - - -0.26554M 0.89M 0.28M
Total cashflows from investing activities 0.00000M 0.00000M 0.00000M - -
Net borrowings - - - - -
Total cash from financing activities 1.06M 5.21M -1.28255M 30.51M 12.28M
Change to operating activities - - 0.23M 0.59M -1.10546M
Net income -4.78726M -13.81934M -9.92342M -11.20198M -6.34032M
Change in cash -3.52303M -4.33154M -12.02042M 24.22M 7.59M
Begin period cash flow 17.19M 21.52M 33.54M 9.32M 1.73M
End period cash flow 13.67M 17.19M 21.52M 33.54M 9.32M
Total cash from operating activities -4.57441M -9.54558M -10.65155M -6.25784M -4.69758M
Issuance of capital stock 1.06M 5.21M -1.28255M 30.98M 12.79M
Depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Other cashflows from investing activities 0.00000M 0.00000M 0.00000M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.08M 1.60M -1.64163M 0.07M -0.07925M
Sale purchase of stock 1.06M -0.00462M -1.28255M -0.46349M -0.51053M
Other cashflows from financing activities 0.00000M 5.21M -1.28255M -0.00000M -0.51053M
Change to netincome - - 0.67M 3.11M 2.27M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.04422M 1.88M -1.64163M 0.07M -0.07925M
Stock based compensation 1.42M 1.43M 0.59M 3.07M 2.28M
Other non cash items -0.44791M 0.68M -1.00932M 4.66M 1.36M
Free cash flow -4.57441M -9.54558M -10.65155M -6.25784M -4.69758M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RAC
Race Oncology Ltd		 0.04 1.72% 2.36 - - 128.57 17.27 -21.5133
CSL
CSL Ltd		 -1.98 1.37% 142.58 16.70 19.49 4.61 2.68 3.87 11.63
TLX
TELIX Pharmaceuticals Ltd		 -0.24 2.18% 10.76 - 1000.00 4.25 5.68 3.34 76.39
MSB
Mesoblast Ltd		 0.01 0.46% 2.19 - 454.55 43.02 3.19 28.08 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.2 1.57% 12.55 53.70 45.66 24.19 4.61 19.56 57.40

Reports Covered

Stock Research & News

View All

Profile

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin. It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.

Race Oncology Ltd

Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Phillip R. Lynch CEO, MD & Director NA
Dr. Daniel Tillett Chief Scientific Officer & Exec. Director NA
Ms. Christina Manfre Chief Financial Officer NA
Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP Interim Chief Medical Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Daniel Tillett Chief Executive Officer NA
Dr. Peter M. Smith Ph.D. Executive Director 1963
Prof. Tim Hammond Interim Chief Scientific Officer NA
Dr. Michelle Rashford Chief Medical Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.